$ 496.80
Details
The RPA-T8 monoclonal antibody specifically binds to CD8 alpha (CD8α). CD8α is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily. CD8α is expressed by the majority of thymocytes, by subpopulations of αβ T cells and γδ T cells and by some NK cells. Cell surface CD8α is expressed either as a disulfide-linked homodimer (CD8αα) or as a heterodimer (CD8αβ) when disulfide-bonded to a CD8 beta chain (CD8β). CD8-positive αβ T cells coexpress both CD8αα homodimers and CD8αβ heterodimers whereas some γδ T cells and NK cells express CD8αα homodimers. CD8 plays important roles in T cell activation and selection. The extracellular IgSF domain of CD8α binds to a non-polymorphic determinant on HLA class I molecules (α3 domain) and enables CD8 to function as a co-receptor with MHC class I-restricted TCR during T cell recognition of antigen. The cytoplasmic domain of CD8α associates with Lck, a Src family protein tyrosine kinase that is involved in intracellular signaling. The RPA-T8 and HIT8a (Cat. No. 555337) monoclonal antibodies are not cross-blocking. The antibody was conjugated to Brilliant Violet 421 and has been developed in collaboration with Sirigen. With an Ex Max of 407-nm and Em Max at 421-nm, Brilliant Violet 421 can be excited by the violet laser and detected in the standard Pacific Blue filter set (eg, 450/50-nm filter). Brilliant Violet 421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.Host Species: MouseClone: RPA-T8Isotype: IgG1, κSpecies Reactivity: HumanFlow Cytometry
